clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bacteriuria D001437 7 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bradycardia D001919 13 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Cindoruk M et al. Influence of H pylori on plasma ghrelin in patients without atrophic gastritis. 2007 World J. Gastroenterol. pmid:17461454
Choi HS et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22654429
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Hwang JJ et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. 2015 World J. Gastroenterol. pmid:25945019
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Lee HJ et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. 2015 World J. Gastroenterol. pmid:25574111
Mamori S et al. Age-dependent eradication of Helicobacter pylori in Japanese patients. 2010 World J. Gastroenterol. pmid:20806435
Yoon JH et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. 2012 World J. Gastroenterol. pmid:23236238
Buzás GM and Józan J First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. 2006 World J. Gastroenterol. pmid:16981260
Babic Z et al. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. 2005 World J. Gastroenterol. pmid:15884110
Zhang L et al. Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. 2006 World J. Gastroenterol. pmid:16804982
Chang CC et al. Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils. 2005 World J. Gastroenterol. pmid:15742400
Feng LY et al. Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. 2005 World J. Gastroenterol. pmid:15742421
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Chen KY et al. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. 2015 World J. Gastroenterol. pmid:26420970
Salimi A et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. 2016 Xenobiotica pmid:26068526
Pan W et al. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. 2013 Xenobiotica pmid:22830954
Kanayama N et al. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. 2007 Xenobiotica pmid:17484517
Burt HJ et al. IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. 2010 Xenobiotica pmid:20230210
Kubo JI et al. Pharmacokinetic evaluation of high pulmonary disposition of clarithromycin after systemic administration. 2002 Xenobiotica pmid:12419017